| Date | Title | Description |
| 04.10.2024 | Solar Surge and Housing Hurdles: A Snapshot of India's Real Estate and Energy Landscape | India's landscape is shifting. The sun is rising on solar energy, while the housing market is showing mixed signals. Alpex Solar is stepping into the spotlight, investing heavily in solar cell production. Meanwhile, housing sales are up, bu... |
| 04.10.2024 | Alpex Solar to invest Rs 6.42 billion in 1.6 GW solar cell production capacity
Housing sales up 5% to 87,108 units across 8 cities in Q2 FY25: Report
Telangana HC grants bail to Nizampet commissioner ... | POWER & RENEWABLE ENERGY Alpex Solar to invest Rs 6.42 billion in 1.6 GW solar cell production capacity
04 Oct 2024 2 Min Read CW Team
Alpex Solar announced its entry into solar cell manufacturing, with plans to establish a 1.6-gigawatt... |
| 04.10.2024 | Housing sales up 5% to 87,108 units across 8 cities in Q2 FY25: Report
Telangana HC grants bail to Nizampet commissioner in HYDRAA case
NRI duped of Rs 30.6 million by Hyderabad real estate company
Al... | Real Estate Housing sales up 5% to 87,108 units across 8 cities in Q2 FY25: Report
04 Oct 2024 2 Min Read CW Team
Housing sales experienced a 5 per cent annual increase during the July-September period, reaching 87,108 units across eight ma... |
| 27.02.2024 | ENGIE announces $1bn Tax Equity Financing for more than 1.3 GW of U.S. Renewables Assets | - |
| 10.01.2024 | Juniper Green to Invest Rs 80 Bn in 1 GW Renewable Projects | POWER & RENEWABLE ENERGY Juniper Green to Invest Rs 80 Bn in 1 GW Renewable Projects
10 Jan 2024 CW Team
Juniper Green Energy is set to make a substantial investment of Rs 80 billion for the development of 1 gigawatt (GW) of renewable e... |
| 17.11.2023 | Grew Energy Invests Rs 60 Bn in 6 GW Solar Capacity | POWER & RENEWABLE ENERGY Grew Energy Invests Rs 60 Bn in 6 GW Solar Capacity
17 Nov 2023 CW Team
Grew Energy is set to make a substantial investment of Rs 60 billion to establish a massive 6 gigawatts (GW) solar manufacturing capacity i... |
| 28.12.2022 | ACWA Power to Invest $2.4 Billion for 1.5 GW Wind Projects in Uzbekistan | - |
| 01.12.2022 | AMEA Power to Invest $1.1 Billion in Egypt for 1 GW Wind and Solar Projects | - |
| 06.12.2021 | NRG Closes 4.8 GW Asset Sale and Announces $1 Billion Share Repurchase Program | NRG Energy Inc. (NYSE: NRG) has closed the previously announced sale of approximately 4,850 MWs of fossil generating assets from its East and West regions to Generation Bridge, an affiliate of ArcLight Capital Partners. At Closing, NRG rece... |
| 21.09.2021 | Rare Cannabinoid Company Launches World's First Pure CBDV Oil - Cannabidivarin Is Being Researched For Autism, Muscular Dystrophy, Rett Syndrome and Seizures | Rare Cannabinoid Company adds CBDV to its apothecary of pure cannabinoid oil tinctures and blends of THCV, Delta-8-THC, CBN, CBG, CBDA, CBC, Rare Hawaiian CBD. "We're very excited to be the first to bring a pure CBDV product to market ... |
| 28.07.2021 | Premier Energies to invest Rs 1,200 cr to expand capacity to 3 GW | POWER & RENEWABLE ENERGY Premier Energies to invest Rs 1,200 cr to expand capacity to 3 GW
28 Jul 2021 CW Team
Premier Energies, a solar equipment manufacturing firm of India, plans to make an investment of about Rs 1,200 crore in two y... |
| 29.04.2021 | GW PHARMACEUTICALS PLC
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation | LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces tha... |
| 20.04.2021 | GW PHARMACEUTICALS PLC
GW PHARMACEUTICALS PLC : Other Events (form 8-K) | Item 8.01 Other Events.
As previously disclosed, on February 3, 2021, GW Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales ("GW"), entered into a transaction agreement with Jazz Pharmac... |
| 20.04.2021 | JAZZ PHARMACEUTICALS PLC
JAZZ PHARMACEUTICALS PLC : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statem... | Item 1.01 Entry into a Material Definitive Agreement.
On April 20, 2021, Jazz Pharmaceuticals Public Limited Company ("Jazz," the "Company," "we" or "our"), as guarantor, and certain of its wholly-own... |
| 20.04.2021 | GW PHARMACEUTICALS PLC
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex | – Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe –
– TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 –
LON... |
| 26.02.2021 | GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex | LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces tha... |
| 23.02.2021 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results | DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021.
"In 2020, we made meaningful progres... |
| 23.02.2021 | Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results | |
| 16.02.2021 | GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress | – Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year –
– Total Epidiolex® net product sales of $144.1 million for the fourth quarter and $510.5 million for the full year –
– Previously announced agre... |
| 04.02.2021 | Tilray stock extends rally as Democrat lawmakers promise to push marijuana reforms | A worker checks cannabis plants inside the Tilray factory hothouse in Cantanhede, Portugal April 24, 2019. REUTERS/Rafael Marchante
Shares of Tilray surged more than 22% Wednesday, buoyed by encouraging words from lawmakers on ending federa... |
| 04.02.2021 | Tilray stock extends rally as Democrat lawmakers promise to push marijuana reforms | Shares of Tilray surged more than 22% Wednesday, buoyed by encouraging words from lawmakers on ending federal prohibition of marijuana.
Shares of cannabis companies Aurora, Aphria, and Cronos are also trading higher.
Senate Majority Leader ... |
| 03.02.2021 | GW Pharmaceuticals soars 46% after Jazz Pharma agrees to $7.2 billion acquisition of the CBD biopharma company | GW Pharmaceuticals stock soared 46% on Wednesday after Jazz Pharma said it would buy the company for $7.2 billion.
The proposed deal will include $200 in cash and $20 in shares of Jazz Pharma, and is expected to close in the second quarter ... |
| 23.12.2020 | Marijuana Giant Canopy Growth Claims Ownership Of Oil Extraction Technology And Sues GW Pharma For Patent Infringement | Cannabis oil is the viscous, sticky, THC or CBD-rich sludge found in popular vaporizer pens and oil cartridges. To make cannabis oil, processes using liquid carbon dioxide to extract the active ingredients from the plant material is one of ... |
| 15.11.2020 | Как инвестировать в компанию по изучению галлюциногенных грибов? | 12 12 комментариев
916 просмотров
В 2014 году моя жена проснулась в холодном поту посреди ночи. Она пожаловалась на сердце и одышку. Через пару дней приступ повторился. Физически она была здорова. После массы анализов ей поставили диагноз «... |
| 24.09.2019 | GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union | GW Pharma’s cannabis-derived medicine for epilepsy has won European endorsement, more than a year after the British drugmaker secured its landmark US approval.
The medicine, christened Epidyolex in the EU, is a plant-der... |
| 24.09.2019 | GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval | The drug won Food and Drug Administration approval last year for the same indication in the U.S., where it is marketed as Epidiolex. The EC approval encompasses all 28 countries of the European Union, as well as the European Economic Area n... |
| 13.08.2019 | A groundbreaking drug made from cannabis has brought hope for kids with rare seizure disorders. We talked to parents, doctors, and the company's CEO to find out if it lives up the hype. | April Krowel
Four-year-old Aubrie Krowel has been taking a new CBD drug for her rare form of childhood epilepsy since April.
Advertisement
A new drug that's made from a component of cannabis called CBD became available in the US last year t... |
| 07.05.2019 | GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory | Shares of GW opened Tuesday morning nearly 9 percent above their Monday closing price of $180.09 on the Nasdaq before settling back down to $184.32 in afternoon trading.
According to the data, patients receiving Epidiolex at 25mg per kilogr... |
| 19.12.2018 | Sandoz gets into the weeds with cannabis medical product manufacturer Tilray | Shares of Tilray on the Nasdaq were up nearly 10 percent on the news when markets opened Tuesday and are currently trading around 20 percent above their Monday closing price of $65.89. The company went public in June.
To be sure, the deal i... |
| 01.11.2018 | GW's cannabis-derived drug Epidiolex finally launches in the US with an average list price of $32,500 | Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States.
The drug comprises cannabidiol (CBD) with a... |
| 11.09.2018 | Why The Adult Cannabis Market Could Kill Its Medical Counterpart | As more states continue to legalize recreational marijuana—the current tally is nine and Washington, D.C.--speculation is afoot among industry pundits that this could be the precursor to a major slowdown, if not death knell, for the medical... |
| 02.07.2018 | GW Pharmaceuticals gets first FDA approval for CBD-based drug | Other companies developing cannabis-based pharmaceuticals include Kalytera Therapeutics, a Novato, California-based company developing CBD-based drugs for pain, graft versus host disease and others; Zynerba Pharmaceuticals, based in Devon, ... |
| 13.10.2017 | The Future of Pharmaceutical Cannabis May Be Cultured, Not Cultivated | Hyasynth Bio is a Montreal-based biotech startup that has developed a way to produce the active compounds in cannabis without ever growing a plant. Cannabis’s most plentiful active compounds, the non-psychotropic cannabidiol (CBD), and the ... |
| 07.02.2017 | GW touts positive survival benefit in small brain cancer study; Ablynx files for ultra-rare disease drug OK | • GW Pharma is touting claims that a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) produced positive survival benefits in a small study of 21 patients with recurrent glioblastoma multiforme, a common... |
| 16.05.2016 | Want to test a marijuana-based drug? Expect a visit from the ‘men in black’ | HOUSTON — The drug shows promise: In one study, it reduced seizures for some children with a crippling epileptic condition. If approved, it would be the first medication specifically for those youngsters.
It would also be the first prescrip... |
| 09.06.2014 | A Comprehensive History of Marijuana's Epilepsy-Treating Compound, CBD | Charlotte Figi at six years old. Photo courtesy of Realm of Caring.
Hundreds of families have already relocated to Colorado in search of non-psychoactive cannabis-derived medicine for their severely ill children, sparking a long waiting lis... |
| 08.07.2005 | GW Capital Partners closes India Value Fund II on $150m | New limited partners included Partners Group, CDC, Grove Street Advisors and PPM. The level of international demand for |
| - | GW Pharmaceuticals’ cannabis-derived epilepsy drug wins European approval | A company developing drugs derived from cannabis has won approval for its epilepsy medicine in Europe.
Cambridge, U.K.-based GW Pharmaceuticals said Monday that the European Commission approved Epidyolex (cannabidiol) as an adjunctive thera... |
| - | GW Pharmaceuticals gets first FDA approval for CBD-based drug | The first drug that uses the marijuana plant-derived ingredient cannabidiol won approval from the Food and Drug Administration last week.
GW Pharmaceuticals, a British drugmaker, announced June 25 the approval of Epidiolex oral solution for... |
| - | Tilray stock extends rally as Democrat lawmakers promise to push marijuana reforms | A worker checks cannabis plants inside the Tilray factory hothouse in Cantanhede, Portugal April 24, 2019. REUTERS/Rafael Marchante
Redeem now
Shares of Tilray surged more than 22% Wednesday, buoyed by encouraging words from lawmakers on en... |
| - | Sandoz gets into the weeds with cannabis medical product manufacturer Tilray | A Canadian company that makes cannabis-based medical products has taken its relationship with Swiss drugmaker Novartis’ generics arm global.
Nanaimo, British Columbia-based Tilray said Tuesday that it signed a global framework agreement wit... |
| - | GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory | The company that nearly a year ago became the first to receive Food and Drug Administration approval for a cannabinoid-based drug has another positive Phase III trial under its belt.
Cambridge, UK-based GW Pharmaceuticals said Monday that i... |
| - | Hero Future Energies to invest $20 billion to boost renewable energy capacity to 30 GW by 2030 | - |